Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Josh Harder has won his congressional race to become the only venture capitalist in the House of Representatives

The entire race was effectively a referendum on Silicon Valley.

Democratic candidate for California’s 10th Congressional District Josh Harder places his ballot inside a ballot box
Democratic candidate for California’s 10th Congressional District Josh Harder places his ballot inside a ballot box
Democratic candidate for California’s 10th Congressional District Josh Harder
Alex Edelman / Getty

A tech investor is in a dead heat in a competitive congressional race to become the sole venture capitalist serving in the House of Representatives.

Update: After another week of counting votes, he has won, according to the Associated Press.

The Democratic candidate, Josh Harder, is trying to oust a GOP incumbent in a campaign that turned into something of a referendum on Silicon Valley. Harder, who most recently served as a vice president at Bessemer Venture Partners, is battling the four-term Republican incumbent, Jeff Denham, but the race remains too close to call, according to the Associated Press.

Denham, with 50.6 percent of the vote, has a lead of about 1,300 votes as of Wednesday morning. Although 100 percent of precincts have reported results, election officials will have to account for absentee and provisional ballots in a process that could last awhile. Neither Harder nor Denham has conceded.

But Harder was not merely a venture capitalist. His entire race was defined by his venture capital past, with Denham casting him as a Silicon Valley insider who was responsible for Bessemer portfolio companies that shifted jobs overseas. Denham, on the other hand, called himself the closest thing to the opposite of a venture capitalist — a farmer — in a rural district centered on Modesto.

Harder was reluctant to talk about his background in tech investing, taking pains to stress the more homegrown parts of his biography.

According to industry trade group the National Venture Capital Association, the only other current member of Congress that it’s aware of having a background in traditional venture capital is Mark Warner, a Democrat from Virginia, who was elected to the Senate in 2008.

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh